Booking Holdings vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Norwalk CT online travel (NASDAQ: BKNG) at $23.74B 2024 revenue (+11%), $166B gross bookings; $20B buyback authorized Jan 2025, 10% dividend increase, Booking.com dominant in European accommodations competing with Expedia and Airbnb.
About
Booking Holdings Inc. is a Norwalk, Connecticut-based online travel platform — publicly traded on NASDAQ (NASDAQ: BKNG) as an S&P 500 Consumer Discretionary component — operating the world's largest portfolio of online travel brands including Booking.com (global accommodations leader), Priceline (US discount travel), Agoda (Asia-Pacific travel), KAYAK (metasearch), OpenTable (restaurant reservations), and Rentalcars.com across 220+ countries and territories through approximately 24,800 employees. In fiscal year 2024, Booking Holdings reported $23.74 billion in revenue (up 11% year-over-year), $5.88 billion in net income, and $166 billion in gross bookings — with Q4 2024 room nights growing 13% and gross bookings up 17% year-over-year. The company maintains a market capitalization exceeding $167 billion as of 2025. In January 2025, Booking Holdings authorized a $20 billion stock repurchase program and increased its quarterly dividend 10% to $9.60 per share, reflecting strong free cash flow generation. CEO Glenn Fogel has led the company since 2017, overseeing both pandemic recovery and the subsequent travel demand surge. Booking.com's accommodation inventory of millions of properties (hotels, vacation rentals, apartments, villas) across 220+ countries represents the broadest accommodation distribution platform in the global travel market.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.